HC Andersen Capital is hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.

Sparekassen Sjælland-Fyn - Præsentation af årsrapporten 2022
Sparekassen Sjælland-Fyn offentliggjorde fredag den 10. februar sit årsregnskab for 2022 efter, at sparekassen i midten af januar var ude og præcisere sin 2022 guidance samtidig med, at man også løftede sløret for sin 2023 forventninger. 

Det endelige resultat før skat for 2022 lander således på DKK 482 mio. og kommer altså ud i toppen af det indsnævrede interval på DKK 478-482 mio., der blev meldt ud i januar i år. Resultatet er dog under 2021 som følge af negative kursreguleringer på DKK -73 mio., men den underliggende bankdrift målt på basisindtjeningen vokser med 16% sammenholdt med året før til DKK 528,1 mio. 

For 2023 gentager sparekassen forventningen om et resultat før skat i intervallet DKK 500-600 mio. og har altså på nuværende tidspunkt udsigt til endnu et stærkt år. 

Udbyttet foreslås til DKK 6,00 pr. aktie, og er således uændret i forhold til niveauet fra 2021, men ventes senere at blive suppleret af et aktietilbagekøb, som der dog ikke sættes beløb på endnu. 

Mød og stil spørgsmål til sparekassedirektør Lars Bolding en gennemgang af regnskabet for 2022, og de vigtigste tendenser i året der gik, samt et kig ind i 2023 og de forventninger Sparekassen Sjælland-Fyn har kommunikeret til markedet.

Disclaimer: HC Andersen Capital modtager betaling fra Sparekassen Sjælland-Fyn for en Digital IR/Corporate Visibility abonnementsaftale. /Rasmus Køjborg, CFA Kl. 08:45 d. 10/02-2023.

Monday 20th of february 12:00 - 12:30
 
Sign up via. Link


Note: This event is in Danish
__________________________________

NeoDynamics - Presentation  of annual accounts  2 022
NeoDynamics had a very busy 2022 and ready to launch Neonavia in US - 2023. Medtech company NeoDynamics got FDA approval for Neonavia in US early fall 2022 and they are now ready for full commercialization of NeoNavia in US - 2023.  

NeoDynamics have a very strong patent portfolio in major European markets, China, and US. It is the company's vision that NeoDynamics pulse technology becomes the new standard for all ultrasound-guided breast cancer biopsies, improving both precision and reliability, and contributing to correct diagnoses and enable individualised treatment without delays for every individual breast cancer patient. "The NeoNavia biopsy system can safely increase the precision of ultrasound-guided, technically challenging biopsies such as in axillary lymph nodes."  

Meet CFO Aaron Wong when he presents the Annual Accounts. As always you are more than welcome to post questions during the presentation.  

Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup, 1:15 PM 17 January 2023.

Monday 20th of february 13:00 - 13:30

Sign up via. Link


Zerion Pharma - Regulatory environment and strategic partnerships
Meet Zerion Pharma's management and regulatory team CEO Ole Wiborg, CFO Jakob Dynnes Hansen, and Mónica González VP Regulatory Affairs who will briefly run through the investment proposal and business case. The management will focus on the regulatory environment governing the Dispersome(TM) technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company's strategic partnerships.  

Zerion Pharma is a non-listed Danish company seeking E2-3m in a private placement round.  

The company aims to make a real difference in health care with its Dispersome(TM) technology in relation to the formulation of new and existing drugs. Poor drug solubility is one of the main reasons for drug development failure. ZERION has a solution - Dispersome® - a technology that increases the chance of success for new drug development, allows for improvement of existing drugs enabling more new drugs to reach the market and leads to improved treatment of patients as well as reduced toxic waste. The Dispersome® technology makes it possible to reduce the number of active drugs by up to 75%.  

Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a Digital IR/Corporate Visibility agreement. Zerion Pharma is a private company (i.e. not listed on a regulated stock market). Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise. /Claus Thestrup 9.49 PM 09/02-2023.

Monday 20th of february 14:30 - 15:00

Sign up via. Link


Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations. 
 

Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
 

HC Andersen Capital digitizes the relationship between listed companies and investors. We work long-term for companies that want more visibility in the market. #DemocraticIR - HC Andersen Capital works to democratize access to the financial market.

https://news.cision.com/hc-andersen-capital/r/hc-andersen-capital-events-20-02--meet-the-top-management-in-sparekassen-sjaelland-fyn--neodynamics-,c3718503

(c) 2023 Cision. All rights reserved., source Press Releases - English